Abstract:Background: Our preliminary research found that STAT3, IL-17A, and IL-21 expressed in cGVHD patients. So, we provide the blocking STAT3 signal to the induction of Treg cells differentiation, and to provide experimental basis on new targets of cGVHD immunotherapy.Methods: 1. Mice spleen CD4+ CD62L+ naiveT cells were separated by immune magnetic bead and then activated for 72 h. After 96 h infection with STAT3-shRNA and negative control lentivirus, the Th subgroup proportion were measured by flow cytometry. Th related cytokines levels test by Luminex. Real time quantitative PCR was to detect STAT3 and Th subgroup related transcription factor mRNA levels. CD117+ mouse bone marrow stem progenitor cells were sorted by flow cytometry, and transfected by STAT3-shRNA. Inhibition of STAT3 gene in mRNA level was measured at 96 h. Cell proliferation activity was test with CCK8 kit, and cell apoptosis rate determined by flow cytometry. Differentiation of CD117+ cells was induced by 2.2% of methyl cellulose and different cytokines.2. BALB/c female mice, after the linear accelerator 700cGy of whole body irradiation, accepted miHA mismatched male B10. D2 mice bone marrow cells and spleen cells (8 x 106, 1:1). Randomly assigned 6 mice of cGVHD clinical score of 0.6 or above to each group. After STAT3-shRNA or negative control lentivirus treatment, the observe end point was 58th day after transplantation. clinical and pathologic scores compared. Th17 and Treg cells measured by flow cytometry. Th related cytokines measured by Luminex. Purpose genes in blood and protein expression levels in target organs were found by Q-PCR and western blot test, respectively.Results: 1. Th17 / Treg ratio of shRNA group was significantly decreased than that in the NC group (P 0.05).2. After 50th day, shRNA treatment group appear hair recovery, energy recovery, weight gain, shortness of breath better, mean of cGVHD score decreased. At the 58th day, clinical scores of cGVHD between shRNA treatment group and the negative control group overall mean difference was statistically significant (P u003c 0.05). cGVHD pathological score of lungs in shRNA treat group reduced (P u003c 0.05). STAT3mRNA levels in peripheral blood, phosphorylated STAT3, and STAT3 expression level of lung declined than control groups. proportion of Th17 / Treg cells of spleen was significant reduced in shRNA group, compared with negative control group (P u003c 0.05).Conclusion: 1. STAT3 knocking down in naive CD4 + Th cells induced the increased Treg cells, and the decreased Th17 cells. IL-2 confirmed to promote the growth of Treg cells. It speculated that blocking STAT3 might bring Th9 cells differentiation. STAT3 blocking in CD117+ stem progenitor cells have no significant effect on the proliferation, apoptosis and differentiation, validation the safety of STAT3-shRNA.2. STAT3-shRNA treatment cGVHD mice in vivo achieved curative effect. main target organs was the lung, which might be closely related to the fall in the proportion of Th17 /Treg. STAT3 may be used as a new target for immunotherapy of cGVHD.Acknowledgement The project was sponsored by grants from National Natural Science Foundation of China (No. 30972790; No.81270648; No.81370665; No.81300446), Provincial Natural Science Foundation of Guangdong (No. S2012010009560), Provincial Science and Technology Planning Project of Guangdong (No.2013B021800186; No.2013B021800201), and Science and Technology Planning Project of Guangzhou (No. 201400000003-4, 201400000003-1).Disclosures No relevant conflicts of interest to declare.

CD3 Mab Treatment Ameliorated the Severity of the Cgvhd-Induced Lupus Nephritis in Mice by Up-Regulation of Foxp3+ Regulatory T Cells in the Target Tissue: Kidney

Down Regulation Of Cxc Chemokine Receptor 3 Impedes The Ability Of Anti-Cxcr3 Antibody To Block Graft-Versus-Host Disease

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus

AB0045 MESENCHYMAL STEM CELLS INHIBIT THE ACTIVATED COMPLEMENT C5 BY CLUSTERIN IN LUPUS NEPHRITIS

The Regulation of the Treg/Th17 Balance by Mesenchymal Stem Cells in Human Systemic Lupus Erythematosus

TGF-β-Induced CD8+CD103+ Regulatory T Cells Show Potent Therapeutic Effect on Chronic Graft-versus-Host Disease Lupus by Suppressing B Cells.

TLR4+CXCR4+ Plasma Cells Drive Nephritis Development in Systemic Lupus Erythematosus

Essential Roles Of Tgf-Beta In Anti-Cd3 Antibody Therapy: Reversal Of Diabetes In Nonobese Diabetic Mice Independent Of Foxp3(+) Cd4(+) Regulatory T Cells

Determination of Pathological Factors Involved in Lupus Nephritic Mice with Cgvhd

Reduction of Cell Surface T-Cell Receptor by Non-Mitogenic CD3 Antibody to Mitigate Murine Lupus

CXCR3 deficiency decreases autoantibody production by inhibiting aberrant activated T follicular helper cells and B cells in lupus mice

5-aminolevulinic acid combined with sodium ferrous citrate ameliorated lupus nephritis in a mouse chronic graft-versus-host disease model

Therapeutic Effect of Leflunomide on the Development of Experimental Lupus Nephritis in Mice

Rapamycin Treatment Alleviates Chronic GVHD-Induced Lupus Nephritis in Mice by Recovering IL-2 Production and Regulatory T Cells While Inhibiting Effector T Cells Activation

Lupus Recipe inhibits cGVHD-induced lupus nephritis in mice and promote renal LC3-associated autophagy

LangChuangHeJi Decoction Ameliorates Lupus Via Preventing Accumulation of CD138+ T Cells in MRL/lpr Mice.

Reverse Effect of CD4+CD25+ Regulatory T Cells on Lupus-Like Murine

CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice

Protective effects of polyclonal iTreg induced by IL-2 and TGF-{beta} on a lupus-like syndrome

Blocking Stat3 To Regulate The Balance Of Th17/Treg In Cgvhd Therapy